Business, energy, technology, markets and global industry news from Business News Today

Tru Niagen

PharmaDeviceNews Tru Niagen
Representative image: Niagen Bioscience’s investor conference push highlights the growing commercial debate around NAD+ science, healthy aging, Tru Niagen, Niagen Plus, and whether healthspan-focused platforms can convert clinical credibility into durable market confidence.
Pharma & Biotech

Why Niagen Bioscience’s next investor meetings could sharpen the NAD+ market debate

NAD+ is hot, but credibility is scarce. Niagen Bioscience now has to prove healthspan science can support durable investor trust.

Read More